Systematic review of melatonin levels in individuals with complete cervical spinal cord injury

References

• Middleton B. Measurement of melatonin and 6-sulphatoxymelatonin. Methods Mol Biol 2006;324:235–54.
   PubMedGoogle Scholar
• Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186–95.
   PubMed Web of Science ®Google Scholar
• Brown EN, Choe Y, Shanahan TL, Czeisler CA. A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997;272(3 Pt 1):E506–16.
   PubMedGoogle Scholar
• Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 2005;20(4):291–303.
   PubMed Web of Science ®Google Scholar
• Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005;9(1):11–24.
   PubMed Web of Science ®Google Scholar
• Arendt J. Melatonin and human rhythms. Chronobiol Int 2006;23(1–2):21–37.
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Korf HW, Wicht H. Synchronizing effects of melatonin on diurnal and circadian rhythms. Gen Comp Endocrinol 2018;258:215–21.
   PubMed Web of Science ®Google Scholar
• Kaptanoglu E, Tuncel M, Palaoglu S, Konan A, Demirpençe E, Kilinç K. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J Neurosurg 2000;93(1 Suppl):77–84.
   PubMed Web of Science ®Google Scholar
• Cayli SR, Kocak A, Yilmaz U, Tekiner A, Erbil M, Ozturk C et al. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur Spine J 2004;13(8):724–32.
   PubMed Web of Science ®Google Scholar
• Gül S, Celik SE, Kalayci M, Taşyürekli M, Cokar N, Bilge T. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg Neurol 2005;64(4):355–61.
   PubMedGoogle Scholar
• Erten SF, Kocak A, Ozdemir I, Aydemir S, Colak A, Reeder BS. Protective effect of melatonin on experimental spinal cord ischemia. Spinal Cord 2003;41(10):533–8.
   PubMed Web of Science ®Google Scholar
• Yang L, Yao M, Lan Y, Mo W, Sun YL, Wang J et al. Melatonin for spinal cord injury in animal models: a systematic review and network meta-analysis. J Neurotrauma 2016;33(3):290–300.
   PubMed Web of Science ®Google Scholar
• Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y et al. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One 2016;11(5):e0154427.
   PubMed Web of Science ®Google Scholar
• Shen Z, Zhou Z, Gao S, Guo Y, Gao K, Wang H et al. Melatonin inhibits neural cell apoptosis and promotes locomotor recovery via activation of the Wnt/β-Catenin signaling pathway after spinal cord injury. Neurochem Res 2017;42(8):2336–43.
   PubMed Web of Science ®Google Scholar
• Li C, Chen X, Qiao S, Liu X, Liu C, Zhu D et al. Melatonin lowers edema after spinal cord injury. Neural Regen Res 2014;9(24):2205–10.
   PubMed Web of Science ®Google Scholar
• Aydemir S, Dogan D, Kocak A, Dilsiz N. The effect of melatonin on spinal cord after ischemia in rats. Spinal Cord 2016;54(5):360–3.
   PubMed Web of Science ®Google Scholar
• Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011;51(3):270–7.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Ho KY, Castroviejo DA, Zakaria R, Brzezinski A, Lauterbach EC. Melatonin and pain: therapeutic applications. In: Venkataramanujam S, Brzezinski A, Oter S, Shillcut SD, (eds.), Melatonin and Melatonergic Drugs in Clinical Practice. New York: Springer Press; 2014. p. 221–34.
   Google Scholar
• Gonçalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 2016;87(10):1127–32.
   PubMed Web of Science ®Google Scholar
• Nduhirabandi F, Lochner A. Melatonin and the metabolic syndrome. In: Venkataramanujam S, Brzezinski A, Oter S, Shillcut SD (eds.), Melatonin and Melatonergic Drugs in Clinical Practice. New York: Springer Press. 2014. p. 71–95.
   Google Scholar
• Mesri Alamdari N, Mahdavi R, Roshanravan N, Lotfi Yaghin N, Ostadrahimi AR, Faramarzi E. A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Horm Metab Res 2015;47(7):504–8.
   PubMed Web of Science ®Google Scholar
• Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res 2011;50(3):261–6.
   PubMed Web of Science ®Google Scholar
• Myers J, Lee M, Kiratli J. Cardiovascular disease in spinal cord injury. Am J Phys Med Rehabil 2007;86(2):142–52.
   PubMed Web of Science ®Google Scholar
• Citera G, Arias MA, Maldonado-Cocco JA, Lazaro MA, Rosemfett MG, Brusco LI et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000;19:9–13.
   PubMed Web of Science ®Google Scholar
• Hussain SA, Al-Khalifa H, Jasim NA, Gorial FI. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011;50:267–71.
   PubMed Web of Science ®Google Scholar
• Brun J, Claustrat B, Saddier P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995;15:136–9.
   PubMed Web of Science ®Google Scholar
• Masruha MR, de Souza Viera DS, Minett TS, Cipolla-Neto J, Zuckerman E, Vilanova LC et al. Low urinary 6-sulphatoxy-melatonin concentrations in acute migraine. J Headache Pain 2008;9:221–34.
   PubMedGoogle Scholar
• Tabeeva GR, Sergeev AV, Gromova SA. Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan). Zh Nevrol Psikhiatr Im S S Korsakova 2011;111(9):32–6.
   PubMedGoogle Scholar
• Modirian E, Pirouzi P, Soroush M, Karbalaei-Esmaeili S, Shojaei H, Zamani H. Chronic pain after spinal cord injury: results of a long-term study. Pain Med 2010;11(7):1037–43.
   PubMed Web of Science ®Google Scholar
• Cho Y, Ryu SH, Lee BR, Kim KH, Lee E, Choi J. Effects of artificial light at night on human health: a literature review of observational and experimental studies applied to exposure assessment. Chronobiol Int 2015;32(9):1294–310.
   PubMed Web of Science ®Google Scholar
• Stoschitsky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999;55:111–5.
   PubMed Web of Science ®Google Scholar
• Mundigler G, Delle-Karth G, Koreny M, Zehetgruber M, Steindl-Munda P, Marktl W et al. Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med 2002;30(3):536–40.
   PubMed Web of Science ®Google Scholar
• Monteleone P, Forziati D, Orazzo C, Maj M. Preliminary observations on the suppression of nocturnal plasma melatonin levels by short-term administration of diazepam in humans. J Pineal Res 1989;6:253–8.
   PubMed Web of Science ®Google Scholar
• Ursing C, von Bahr C, Brismar K, Rojdmark S. Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol 2005;61:197–201.
   PubMed Web of Science ®Google Scholar
• Karkela J, Vakkuri O, Kaukinen S, Huang WQ, Pasanen M. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 2002;46:30–6.
   PubMed Web of Science ®Google Scholar
• Seifman MA, Gomes K, Nguyen PN, Bailey M, Roseneld JV, Cooper DJ et al. Measurement of serum melatonin in intensive care unit patients: changes in traumatic brain injury, trauma and medical conditions. Front Neurol 2014;5:666.
   Web of Science ®Google Scholar
• Grima NA, Ponsford JL, St. Hilaire MA, Mansfield D, Rajaratnam SM. Circadian melatonin rhythm following traumatic brain injury. Neurorehabil Neural Repair 2016;30(10):972–7.
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang DH, Wang ML, Jiao DR, Pang SF. Rhythms of serum melatonin in patients with spinal lesions at the cervical, thoracic or lumbar region. Clin Endocrinol (Oxf) 1989;30(1):47–56.
   PubMed Web of Science ®Google Scholar
• Kneisley LW, Moskowitz MA, Lynch HG. Cervical spinal cord lesions disrupt the rhythm in human melatonin excretion. J Neural Transm Suppl 1978;13:311–23.
   Google Scholar
• Van Papendorp DH, Theron JJ, Viljoen M, Kruger MC, Steyn ME. Plasma melatonin levels in patients with spinal cord lesions. Med Sci Res 1995;23(3):189–90.
   Google Scholar
• Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000;85(6):2189–96.
   PubMed Web of Science ®Google Scholar
• Alves de Almeida E, Di Mascio P, Harumi T, Spence DW, Moscovitch A, Hardeland R et al. Measurement of melatonin in body fluids: standards, protocols and procedures. Childs Nerv Syst 2011;27:879–91.
   PubMed Web of Science ®Google Scholar
• Benloucif S, Burgess HJ, Klerman EB, Lewy AF, Middleton B, Murphy PJ et al. Measuring melatonin in humans. J Clin Sleep Med 2008;4(1):66–9.
   PubMed Web of Science ®Google Scholar
• Joanna Briggs Institute. JBI critical appraisal – checklist for analytical cross-sectional studies. 2017. Available from http://joannabriggs.org/assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017.pdf.
   Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, Santaguida PL et al. Individual studies in systematic reviews of health care interventions. In: Agency for healthcare research and quality, methods guide for comparative effectiveness reviews. March 2012. AHRQ Publication No. 12-EHC047-EF. Available from www.effectivehealthcare.ahrq.gov/.
   Google Scholar
• Spong J, Kennedy GA, Tseng J, Brown DJ, Armstrong S, Berlowitz DJ. Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3 mg melatonin. Spinal Cord 2014;52(8):629–34.
   PubMed Web of Science ®Google Scholar
• Zeitzer JM, Ku B, Ota D, Kiratli BJ. Randomized controlled trial of pharmacological replacement of melatonin for sleep disruption in individuals with tetraplegia. J Spinal Cord Med 2014;37(1):46–53.
   PubMed Web of Science ®Google Scholar
• Verheggen R, Jones H, Nyakayiru J, Thompson A, Groothuis JT, Atkinson G et al. Complete absence of evening melatonin increase in tetraplegics. FASEB J 2012;26:3059–64.
   PubMed Web of Science ®Google Scholar
• Spong J, Kennedy GA, Brown DJ, Armstrong SM, Berlowitz DJ. Melatonin supplementation in patients with complete tetraplegia and poor sleep. Sleep Disord 2013;2013: Article ID 128197.
   PubMedGoogle Scholar
• Kostovski E, Dahm AEA, Mowinckel MC, Stranda A, Skretting G, Osterud B et al. Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin. Spinal Cord 2015;53:285–90.
   PubMed Web of Science ®Google Scholar
• Fatima G, Sharma VP, Verma NS. Circadian variations in melatonin and cortisol in patients with cervical spinal cord injury. Spinal Cord 2016;54:364–7.
   PubMed Web of Science ®Google Scholar
• Kostovski E, Frigato E, Dahm A, Skretting GA, Mowinkel MC, Sandset PM et al. Melatonin modified peripheral blood cell oscillators in humans. FASEB J 2017;31(1 Suppl):614.3.
   Google Scholar
• Vaughan SE, Badr MS, Kruppe E, Abbas HK, Mukkavilli V, Sankari A. Endogenous night time melatonin is preserved in patients with chronic spinal cord injury. Am J Respir Crit Care Med 2017;195:A4536.
   Web of Science ®Google Scholar
• Hofstra WA, de Weerd AW. How to assess circadian rhythm in humans: a review of literature. Epilepsy Behav 2008;13(3):438–44.
   PubMed Web of Science ®Google Scholar
• Duffy JF, Dijk DJ. Getting through to circadian oscillators: why use constant routines? J Biol Rhythms 2002;17(1):4–13.
   PubMed Web of Science ®Google Scholar
• Moore RY. Neural control of the pineal gland. Behav Brain Res 1996;73(1–2):125–30.
   PubMed Web of Science ®Google Scholar
• Slawik H, Stoffel M, Riedl L, Veselý Z, Behr M, Lehmberg J, et al. Prospective study on salivary evening melatonin and sleep before and after pinealectomy in humans. J Biol Rhythms 2016;31(1):82–93.
   PubMed Web of Science ®Google Scholar
• Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep 2005;28(10):1271–8.
   PubMed Web of Science ®Google Scholar
• Spivak E, Oksenberg A, Catz A. The feasibility of sleep assessment by actigraph in patients with tetraplegia. Spinal Cord 2007;45(12):765–70.
   PubMed Web of Science ®Google Scholar
• Angelousi A, Kassi E, Nasiri-Ansari N, Weickert MO, Randeva H, Kaltsas G. Clock genes alterations and endocrine disorders. Eur J Clin Invest 2018;48: e12927.
   PubMed Web of Science ®Google Scholar
• Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov 2014;13(3):197–216.
   PubMed Web of Science ®Google Scholar
• Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M, et al. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers. J Biol Chem 2015;290(18):11537–46.
   PubMed Web of Science ®Google Scholar